Clinical Trial Update: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for SELIBORDARA, evaluating a triplet of selinexor, bortezomib, and daratumumab in refractory multiple myeloma. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Selinexor (selinexor)
• Velcade (bortezomib)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Refractory Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING